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ABSTRACT 
Objective: The study aimed to analyze the Quality of Life (QoL) of patients utilizing benzodiazepines (BZDs). 
Methods: A prospective interventional study was conducted among 109 patients who met the inclusion criteria. The patients consuming BZDs more 
than the prescribed duration were identified and deprescribed. Deprescribing plan was advised after discussing with the prescribing psychiatrist 
and inappropriate BZD users. The QoL of patient’s pre and post-intervention amongst both the continuing and deprescribed groups was evaluated 
by WHO-QoL BREF questionnaire. 
Results: Mean scores in the domains of physical health (71.48), psychological health (68.74), social relationships (65.15) and environmental health 
(68) among the deprescribed group was higher compared to the maintenance group. Independent t-test statistic for QoL showed a statistical 
significance in all 4 domains with p value<0.05. 
Conclusion: 
Keywords: Life amongst benzodiazepine, Post deprescribing 
The current study emphasizes that deprescribing of BZDs as shared decision model involving the physician, pharmacist and patients 
improves the QoL of the patient. 
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DOI: http://dx.doi.org/10.22159/ijpps.2019v11i8.33960 
 
Deprescribing is a newer concept described as “the process of 
withdrawal of potentially inappropriate medications, supervised by 
a health care professional with the goal of improving outcomes by 
tapering, discontinuing or prescribing medications on SOS basis”[1]. 
Benzodiazepines (BZDs) are widely prescribed in the short-term 
treatment of anxiety disorders and insomnia. Despite 
recommendations for transient or short term use i. e for a duration 
not exceeding 2-4weeks, prolonged use is a widespread 
phenomenon in medical practice [2]. Chronic BZD use i. e more than 
3months duration may lead to distressing adverse effects such as 
dependence, tolerance and cognitive impairments [3, 4]. However, a 
recent survey conducted in India revealed that patients take 
medications for longer durations than required due to health 
literacy issues Kamath et al. (2017) [5]. In consequence, clinical 
pharmacists and psychiatrists have a vital role to play in educating 
the patient’s on deprescribing practices thereby increase the 
patient’s medication knowledge, promote lifestyle modifications and 
thus help in enhancing the patients Quality of Life (QoL) [1,5]. The 
literature reveals that none of the studies are conducted to evaluate 
the QoL among the inappropriate BZDs users and this is the first 
study in India that has looked upon assessing the QoL of patients 
before and after deprescribing BZDs. Henceforth, the present study 
was designed to examine the effects of deprescribing BZDs on the 
patient’s overall QoL. 
A prospective, interventional study was designed and conducted 
among 109 patients for a period of 7 mo from August 2017 to 
February 2018 in both the inpatient and outpatient settings of the 
Department of Psychiatry at Ramaiah Medical Hospital, Bangalore. 
Study population included all patients above 18yrs who were already 
prescribed with BZD or Z-drugs. Elderly patients aged above 85yrs, 
patients on antiepileptic medications for a seizure disorder and 
patients with a history of alcohol dependence were excluded from the 
study. 
The study protocol was reviewed and approved by the Institutional 
Ethics Committee. A written informed consent was obtained from 
participants who fulfilled the eligibility criteria and willing to 
participate in the study. The study was performed by collecting 
relevant data from the patient’s prescription forms, case records and 
by interviewing the patients or caretakers in a well-designed patient 
data collection form. The deprescribing plan was suggested after 
discussing with the prescribing psychiatrist and inappropriate BZD 
users. The QoL of patient’s before and after deprescribing in both the 
continuing (maintenance) and deprescribed groups was assessed by 
the WHO-QoL BREF Questionnaire. The patients were followed up 
depending on the duration of tapering and discontinuation of BZDs 
or Z-drugs.  
Data were coded and analysed using IBM SPSS Statistics version 21.0 
for windows. The categorical variables were presented using 
frequencies and percentages. Mean scores of each domain in the 
WHO-QoL Questionnaire i. e physical health, psychological health, 
social relationships and environmental health was calculated for 
both the groups. Independent t-test statistic was employed to test 
the statistical significance in the QoL among both the groups. P-
value<0.05 was considered as statistically significant.  
In the present study of the entire study population, 10(9.1%) 
subjects were appropriate BZD users (<4weeks duration), 36(33%) 
subjects were short term users (<3months) and 63(57.7%) subjects 
were long term users (more than 3months). Post-intervention, 
13(11.9%) were lost during follow up, 56(51.37%) were on 
maintenance BZDs and 40(36.69%) were deprescribed of BZDs. Fig. 
1 shows the mean scores in all the domains of the WHO-QoL BREF 
questionnaire for both the groups. Upon calculating the mean scores 
in all the 4 domains including physical health (71), psychological 
health (68), social relationships (65) and environmental health 
(68),it was found that the scores of the patients deprescribed was 
higher compared to those continuing BZD use.  
Table 1 depicts the independent t-test statistic between follow-ups 
of both the groups. On applying the Independent t-test statistic for 
Pre-Deprescribing (follow up) and Post deprescribing (follow up) it 
was found that there was a statistical significance between the two 
groups in all 4 domains with the p value<0.05. This implies that 
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deprescribing has a positive impact on the patient’s overall QoL. 
This finding is similar to another review which observed a decline 
in QoL in patients continuing BZDs than those who discontinued 
[6]. The drawback of this study included lesser sample size and 
short follow up periods. The literature on the QoL analysis 
amongst the BZDs users is still poor. Henceforth, further studies 
are needed to improve treatment strategies and prevent to 
potential drug-related problems. Implementing deprescribing 
practice among the inappropriate BZD users will help to improve 
the patient’s overall QoL. 
 
 
Fig. 1: Quality of life assessment pre and post intervention amongst both the groups 
 
Table 1: Independent t test statistic for assessing quality of life post intervention amongst both the groups 
Groups Domains t-value Significance (2tailed)  
Maintenance (Follow up) Vs Deprescribed (Follow Up) Domain 1 (Physical Health) 10.67545 <0.005 
Domain 2 (Psychological Health) 10.48822 <0.005 
Domain 3 (Social Relationships) 8.65475 <0.005 
Domain 4 (Environmental Health) 13.5481 <0.005 
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